Sign in to view content

Preclinical Analysis of a Novel Trispecific Antibody, RO-104, for Use in Retinal Neovascular Disease

Subhransu K. Ray, MD, PhD

Video
Published 2024

Related

Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Caroline Baumal, MD, FASRS
Annual Meeting Talks
2021
Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results of the Phase 3 YOSEMITE and RHINE Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2022
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022

Category: AMD-Neovascular

See more